344 related articles for article (PubMed ID: 31590992)
1. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
4. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
5. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
[TBL] [Abstract][Full Text] [Related]
6. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
Grosser R; Cherkassky L; Chintala N; Adusumilli PS
Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
[TBL] [Abstract][Full Text] [Related]
7. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
8. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
11. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
Long B; Brém E; Koyfman A
West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
[TBL] [Abstract][Full Text] [Related]
12. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
Cook J; Litzow M
Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
Mondello P; Nowakowski GS
Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy in multiple myeloma.
Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
[TBL] [Abstract][Full Text] [Related]
15. Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
Hays P; Costello C; Asudani D
Future Oncol; 2019 Dec; 15(36):4235-4246. PubMed ID: 31773980
[TBL] [Abstract][Full Text] [Related]
16. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
19. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
20. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
